PMID- 35935961
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220822
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Sequence Variations Within HLA-G and HLA-F Genomic Segments at the Human 
      Leukocyte Antigen Telomeric End Associated With Acute Graft-Versus-Host Disease 
      in Unrelated Bone Marrow Transplantation.
PG  - 938206
LID - 10.3389/fimmu.2022.938206 [doi]
LID - 938206
AB  - Acute graft-versus-host disease (aGVHD) is defined as a syndrome of an 
      immunological response of graft to the host that occurs early after allogeneic 
      hematopoietic stem cell transplantation (HCT). This disease is frequently 
      observed even in HCT matched for human leukocyte antigen (HLA) alleles at 
      multiple gene loci. Although the HLA region represents complex and diverse 
      genomic characteristics, detailed association analysis is required for the 
      identification of uncharacterized variants that are strongly associated with 
      aGVHD. We genotyped three loci, OR2H2, HLA-F-AS1, and HLA-G, that are located in 
      the 460 kb of HLA telomeric region and statistically analyzed the genotypes 
      including HLA-DPB1 with clinical and transplantation outcomes using 338 unrelated 
      bone marrow transplantation (UR-BMT) patient-donor pairs who were matched for 
      HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 (HLA-10/10). Multivariate analyses 
      demonstrated that HLA-F-AS1 and HLA-DPB1 mismatches were associated with grade 
      II-IV aGVHD (hazard ratio (HR), 1.76; 95% CI, 1.07-2.88; p = 0.026; and HR, 1.59; 
      CI, 1.02-2.49; p = 0.042, respectively). There was no confounding between 
      HLA-F-AS1 and HLA-DPB1 (p = 0.512), suggesting that the HLA-F-AS1 mismatch has a 
      strong effect on aGVHD independently of HLA-DPB1. Moreover, a stratified analysis 
      suggested possible associations of HLA-F-AS1, HLA-DPB1, and/or HLA-G mismatches 
      with grade II-IV aGVHD and the more severe grade III-IV aGVHD. These findings 
      provide new insights into understanding the molecular mechanism of aGVHD caused 
      by HLA-matched UR-BMT.
CI  - Copyright (c) 2022 Suzuki, Morishima, Murata, Tanaka, Shigenari, Ito, Kanga, 
      Kulski, Morishima and Shiina.
FAU - Suzuki, Shingo
AU  - Suzuki S
AD  - Department of Molecular Life Science, Tokai University School of Medicine, 
      Isehara, Japan.
FAU - Morishima, Satoko
AU  - Morishima S
AD  - Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, 
      Second Department of Internal Medicine, Graduate School of Medicine, University 
      of the Ryukyus, Nishihara, Japan.
FAU - Murata, Makoto
AU  - Murata M
AD  - Department of Hematology and Oncology, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Tanaka, Masafumi
AU  - Tanaka M
AD  - Department of Molecular Life Science, Tokai University School of Medicine, 
      Isehara, Japan.
FAU - Shigenari, Atsuko
AU  - Shigenari A
AD  - Department of Molecular Life Science, Tokai University School of Medicine, 
      Isehara, Japan.
FAU - Ito, Sayaka
AU  - Ito S
AD  - Department of Molecular Life Science, Tokai University School of Medicine, 
      Isehara, Japan.
FAU - Kanga, Uma
AU  - Kanga U
AD  - Clinical Immunogenetics Laboratory, Centre for Excellence in Molecular Medicine, 
      Department of Transplant Immunology and Immunogenetics, All India Institute of 
      Medical Sciences, New Delhi, India.
FAU - Kulski, Jerzy K
AU  - Kulski JK
AD  - Department of Molecular Life Science, Tokai University School of Medicine, 
      Isehara, Japan.
AD  - Faculty of Health and Medical Sciences, The University of Western Australia 
      Medical School, Crawley, WA, Australia.
FAU - Morishima, Yasuo
AU  - Morishima Y
AD  - Department of Promotion for Blood and Marrow Transplantation, Aichi Medical 
      University School of Medicine, Nagakute, Japan.
AD  - Department of Hematology and Oncology, Nakagami Hospital, Okinawa, Japan.
FAU - Shiina, Takashi
AU  - Shiina T
AD  - Department of Molecular Life Science, Tokai University School of Medicine, 
      Isehara, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220721
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-F antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Bone Marrow Transplantation/adverse effects
MH  - Genomics
MH  - *Graft vs Host Disease/genetics
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I
MH  - Histocompatibility Testing
MH  - Humans
PMC - PMC9351719
OTO - NOTNLM
OT  - bone marrow transplantation
OT  - genotyping
OT  - graft-versus-host disease
OT  - haplotype
OT  - hitchhiking diversity
OT  - human leukocyte antigen
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/09 06:00
MHDA- 2022/08/10 06:00
PMCR- 2022/01/01
CRDT- 2022/08/08 03:42
PHST- 2022/05/07 00:00 [received]
PHST- 2022/06/20 00:00 [accepted]
PHST- 2022/08/08 03:42 [entrez]
PHST- 2022/08/09 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.938206 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jul 21;13:938206. doi: 10.3389/fimmu.2022.938206. eCollection 
      2022.